Anti-inflammatory mechanisms of macrolide antibiotics include the down-regulation of inflammatory cytokines and lymphocytes. EM and azithromycin (AZM), a 15-memberedring macrolide antibiotic that has clinical effect in the treatment of DPB, were shown to inhibit neutrophil functions in human peripheral blood of chemotaxis and active oxygen generation in vitro5\ EMwas also shown to exhibit a prophylactic effect on lung injury in vivo by using a bleomycin-induced acute lung injury model in rats6). anhydroerythromycin A 6,9-hemiacetal propargyl bromide (EM536) were dissolved in dimethyl sulfoxide (DMSO)to make solutions of0.2, 2 and 6 mM. Each macrolide solution was added to make final concentrations of 1,10 and 30/im. The final concentration of solvent DMSOwas adjusted to 0.5% so that leucocytes would not be damaged. The suspension of leucocytes was preincubated for 60 minutes at 37°C under 5% CO2 in humidified air before chemotaxis with macrolide compoundsor DMSO for control and Nformyl Met-Leu-Phe (fMLP) at a final concentration of 10~8 m for positive control.
Leucocyte chemotaxis was assayed by a modified Boyden-chamber method using a 96-well chemotaxis chamber and polycarbonate filter with 3 /am pore size. The mediumwith fMLPat a final concentration of 2XlO~8M and macrolide compoundswere poured into the wells of lower chamber. Twohundred fi\ of preincubated leucocytes suspension was poured into the wells of the upper chamber at a density of4X 105 cells.
The chamber was incubated for 2 hours at 37°C under 5% CO2 in humidified air. Then, the supernatant was removed from the upper chamber and 200^1 of 2mM
EDTAsolution in PBS (-) was poured into wells to stop migration.
After the chamber was incubated at 5°C for 20 minutes, the lower chamber was centrifuged and the number of leucocytes that migrated through the filter was measured by colorimetric determination of MTTassay at 550 nm.
The inhibition rate of leucocyte chemotaxis was calculated from following equation. "Sample abs." is the OCT. 2000 absorbance of the macrolide compoundadded to the well. "0% release abs." is the absorbance that was executed with no fMLPin the lower chamber, and "fMLP 1(T8m abs." is the absorbance of the fMLPadded to the well at the final concentration of 10~8 m instead of the macrolide sample.
inhibition rate (percent) = 100-(Sample abs.-O% release abs.)X 100 fMLP 1(T8 m abs.-O% release abs.
The chemotaxis inhibition rate of each 14-membered ring macrolide compound is shown in Fig. 2 . Although EM, CAMand RXMhave been reported to The antimicrobial activity (MIC), GMS activity, and chemotaxis of EM, CAM, RXM, and EMderivatives are shown in Table 1 . Comparing MIC with inhibition on chemotaxis, there were no relationships between them. Furthermore, the inhibitory activity on chemotaxis showed no relationship with GMS. EM201 is an intermediary metabolite of EM14'15). EM522 and EM574 are derivatives of EM201 with modified dimethylamino groups. Thus, it might be supposed that EM exhibits strong anti-inflammatory activity when it is metabolized in vivo (Fig. 3) 
